Home Contact Us Send to Colleague Search

	Dec 19 2020 Marketed products in the GI space
	Marketed product in the GI space (idiopathic bowel syndrome, diarrhea, opioid induced constipation) available for acquisition. Client will also consider a distribution partnership.
Add to Outlook Calendar

	Dec 4 2020 Manufacturing facilities needed
	Buy side client seeks to acquire manufacturing facilities in the US. Sterile manufacturing capabilities highly desired. Will consider non-sterile facility with excess capacity.
Add to Outlook Calendar

	Nov 6 2020 Company with sleep apnea asset seeks development partner
	First sleep apnea oral therapy available for co-development. Phase II study completed with positive results. Company has completed first round of financing raising $40 million. Market is highly unsatisfied. Strong IP protection through 2039. Company seeks $120 million to complete Phase III clinical trials.
Add to Outlook Calendar

	Oct 10 2020 Chemotherapy induced nausea and vomiting product available for in-licensing
	Polysorbate free 505(b)(2) product available for in-licensing in the US market. Advantages over other comparable products include favorable side effect profile and ready to use solution. Market research conducted with hospital pharmacists and chemotherapy clinics indicate that the product will be accepted in the marketplace upon approval.
Add to Outlook Calendar

	Sep 20 2020 Schizophrenia asset available for in-licensing
	505(b)(2) product for the treatment of schizophrenia available for in-licensing. Multiple markets available including the US. NDA filed in the US in 2019. Approval expected in 2021. Oral dissolving film makes this product beneficial for patients who resist swallowing. All studies have been completed and a complete response letter issued by the FDA. Manufactured in FDA approved facility.
Add to Outlook Calendar

----------------------------------------------

Commercial Healthcare Partners attended the Biotech Showcase partnering meeting associated with the JP Morgan healthcare conference held in San Francisco January 11-13, 2016. More than 30 meetings were held with potential partners as well as pharmaceutical and biotechnology companies. As a result of these meetings, the following opportunities were identified:

•    Major pharmaceutical company looking to in-license products in all stages of development in the respiratory, autoimmune and allergy therapeutic areas
•    Orphan drug company in Japan seeking to in-license late stage assets for Japanese markets. Current portfolio of products include dysmenorrhea, patent ductus arteriosus and Wilson’s disease
•    Japanese pharma company is seeking products to replace the loss of its flagship product. Areas of interest include CNS, renal disease, behavioral medicine as well as a broad spectrum of additional pharma products
•    Japanese company interested in in-licensing assets for the treatment of autoimmune diseases including arthritis, MS, hepatitis and other chronic diseases. Will consider early stage compounds.
•    Marketing consultant with connections in the middle east will evaluate approved and late stage products for distribution in middle eastern markets.
•    Chinese company interested in buying manufacturing facility in the U.S. Also interested in in-licensing products for the Chinese market including medical devices
•    Well known Indian pharmaceutical manufacturer looking for ANDAs and 505(b)(2) assets for the U.S. market.
•    Chinese pharma company desires to identify products for the Chinese and U.S. markets. Therapeutic areas of interest include oncology, Infectious Disease, auto-immune, neurology/pain management, diabetes, and metabolic disease
•    U.S. based company offers Ex U.S. rights to CNS and GI products
•    Chinese based consulting company looking to make an acquisition in the U.S.
•    U.S. company interested looking to in-license products in the pain management space including opioid based products
•    Large pharma company seeks products in the auto-immune space for the UK market
•    Korean company seeks to in-license pharma products for the Korean market.
•    Pharma company interested in in-licensing products for the treatment of gout, arthritic diseases, and pain management.
•    Israeli company wants to add late stage assets in multiple therapeutic areas for the U.S. market. Will also consider an acquisition.
•    Family owned pharma company wishes to identify assets that are designated as orphan drugs and are undergoing 505(b)(2) regulatory review. Will consider an acquisition.

To explore these opportunities, please contact us.

What's happening NOW!

Commercial Healthcare Partners announces an opportunity to acquire over 160 ANDAs from a single source. Interested bidders can acquire one or more of these assets.

Therapeutic areas include CNS, GI, Dermatology, Ophthalmic solution, anti-infectives, women and men’s health. Please contact CHP with any interest. CDA and minimum bid required.

August 6, 2018

--------

arGentis receives U.S Patent for Arthritis Treatment July 5, 2016

--------

Rockwell Medical
Soluble Ferric Pyrophosphate (SFP)
Phase III asset available from Rockwell Medical

and

License in a Product?
License out a Product?
Find a Partner?
Find a Distributor?
Launch an Approved Product

: Approved 505(b)(2) available for in-licensing:
CHP is pleased to announce the availability of an approved 505(b)(2) product in the cardiovascular space. US rights only. Asset has significant intellectual property rights. This p... View Release